Core Insights - Nurix Therapeutics, Inc. has developed a DEL-AI platform that utilizes a first-in-class DEL Foundation Model trained on proprietary DNA encoded library data to predict novel binders for therapeutically relevant targets, including those previously deemed undruggable [1][2] - The DEL Foundation Model can perform virtual experiments to accurately predict experimental results, demonstrating a correlation between the model's success and the similarity of query sequences to the training set [2] Company Overview - Nurix is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [6] - The company’s pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), along with multiple preclinical candidates [6] Technology and Innovation - The DEL-AI platform integrates advanced machine learning with a collection of over five billion unique DEL compounds, enabling rapid identification of drug candidates for a wide range of proteins [2][4] - The development of the DEL Foundation Model was supported by collaboration with Loka and Amazon Web Services, utilizing AWS SageMaker for scalable infrastructure [3] Research and Development - Nurix's DEL-AI platform is designed to streamline drug discovery workflows, allowing for efficient identification of therapeutic candidates for both internal pipelines and partnerships [2] - The platform leverages extensive datasets from DEL affinity screens to identify binders for virtually any pharmaceutically relevant target [4]